Boatright elected president of ARVO
Researcher Jeffrey Boatright was voted president of the Association for Research in Vision and Ophthalmology (ARVO).
“Jeff Boatright is a terrific choice for president of ARVO, the most prestigious vision research organization in the world,” says Timothy Olsen.
“Jeff’s extraordinary service is well recognized with his selection as president. All of us at the Emory Eye Center are very proud of his recognition and look forward to his positive influence on the organization!”
At Emory Eye Center, Boatright uses molecular and cellular biology techniques to study DNA repair mechanisms with the goal of using them to repair genomic DNA mutations that lead to blindness.
He also uses in-vivo pharmacological approaches to explore the effects of hydrophilic bile acids and other atypical compounds on animal models of retinal degeneration and glaucoma.
This work is funded by the Foundation Fighting Blindness, an unrestricted grant from Research to Prevent Blindness (RPB), the Katz Foundation, and the National Eye Institute (NEI) of the National Institute for Health (NIH).